https://pages.htgaa.org/2026b/farrel-alfaza-marsetyo/index.htmlAbout me I am a year 2 medical student from Yogyakarta Indonesia. I love synthetic biology and would like to find ways to implement it in medicine and clinical practice. Contact info Homework, Labs, and Projects See the nav bar on the left to look through my work for How To Biomanufacture Almost Anything (Fall 2026)!Hugoenhttps://pages.htgaa.org/2026b/farrel-alfaza-marsetyo/week-01-hw-project-ideas/index.htmlMon, 01 Jan 0001 00:00:00 +0000https://pages.htgaa.org/2026b/farrel-alfaza-marsetyo/week-01-hw-project-ideas/index.html(1) What you would like to biomanufacture and why? I want to make a modular production system for rare disease drugs. Rare disease, and their drugs known as orphan drugs are heavily financially disincentivized for big pharma since it’s not profitable. Why is it not profitable? High research price, specialized equipment needed to make it (big pharma are geared to make high demand drugs, and their production infrastructure reflects it), and low demand. Research price will possibly be reduced faster by AI use in biomedical research, but what about production costs? I believe that a modular production system based on living systems and synthetic biology principles could solve this problem. Lowering cost and making orphan drugs more accessible. Who is it for? Fundamentally it is for the patients and their loved ones, while this system could also be marketed to pharma companies to increase their outreach and scalability. I think mainly however this would be an open source platform so that more people could access it. Orphan drugs are very diverse however, and not all orphan drug types are feasible to be produced this way, at least meaningfully. Although theoretically I want this platform to be able to produce all orphan drugs in the world, however, early proof-of-concept prototypes must focus on an orphan drug(s) with these criterias:https://pages.htgaa.org/2026b/farrel-alfaza-marsetyo/week-02-hw-dna-design/index.htmlMon, 01 Jan 0001 00:00:00 +0000https://pages.htgaa.org/2026b/farrel-alfaza-marsetyo/week-02-hw-dna-design/index.html'Week 2 HW: DNA Design' Repository name : Farrel Alfaza Marsetyo Part 1: Define your expression target 1. What molecule are you expressing? A protein, an RNA, or an enzyme (or small set of enzymes) for a pathway. If your HW1 product is a material, food, or chemical, identify the protein(s) that produce it and design for those. I’m expressing a polypeptide enzyme, for this project I’m planning to express one specific enzyme for one specific disease, but in the future I plan to expand it to a class of similar enzymes that targets a number of rare diseases. The specific enzyme I’m planning to express is imiglucerase (brand name Cerezyme)https://pages.htgaa.org/2026b/farrel-alfaza-marsetyo/week-03-hw-cell-free/index.htmlMon, 01 Jan 0001 00:00:00 +0000https://pages.htgaa.org/2026b/farrel-alfaza-marsetyo/week-03-hw-cell-free/index.htmlASSIGNMENT: CFPS REACTION DESIGN FOR SFGFP, PETASE, RETEPLASE A. COMPARE CELL-FREE REACTION COMPOSITIONS (20 minutes) Why does the concentration of potassium glutamate and magnesium glutamate differ between compositions? Which is more sensitive? Ions can help or hinder protein expression in a system. In living cells ions could act as osmolyte which could disrupt osmotic balance between the cell and its environment, but as the cell free system is free of any semipermeable membrane this concern is irrelevant. However, ions could also act as other things, including cofactors to enzymes (especially metal ions), act as a barrier in vital processes that needs different concentration gradients (such as ATP producing systems), or disrupt ionic bonds between amino acid side chains in a protein. Potassium and Magnesium both are cations, and both have extensive biological functions. Potassium acts as the primary intercellular solute in many cells, while magnesium acts as cofactor for many enzymes and as a mimic for calcium. Therefore, I hypothesize that changes magnesium will have a greater effect towards the overall yield and thus is more sensitive. To test this, I plotted the Mg-Glu and K-Glu concentrations of each CFPS formulations in a graph and test their effect towards yield (with the help of claude), the resulting image is as follows:https://pages.htgaa.org/2026b/farrel-alfaza-marsetyo/final-project/index.htmlMon, 01 Jan 0001 00:00:00 +0000https://pages.htgaa.org/2026b/farrel-alfaza-marsetyo/final-project/index.html